Research programme: urological and metabolic disorders therapeutics - 4SC/Schwarz Pharma

Drug Profile

Research programme: urological and metabolic disorders therapeutics - 4SC/Schwarz Pharma

Alternative Names: SC-76803

Latest Information Update: 16 Jan 2008

Price : $50

At a glance

  • Originator 4SC; Schwarz Pharma
  • Developer 4SC
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Erectile dysfunction; Genitourinary disorders

Most Recent Events

  • 16 Jan 2008 Discontinued - Preclinical for Asthma in Germany (unspecified route)
  • 16 Jan 2008 Discontinued - Preclinical for Erectile dysfunction in Germany (unspecified route)
  • 16 Jan 2008 Discontinued - Preclinical for Genitourinary disorders in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top